Pharmaceutical News

RSS

Seasonal flu vaccinations to cost less in Safeway's U.S. Stores

Safeway Inc. (NYSE:SWY) added to its leadership reputation in health care reform and cost control by offering seasonal flu vaccines in its U.S. stores at a substantial savings compared with the cost of doctor-administered vaccines. The lower cost will help consumers and businesses control health care spending in a challenging economy.

20 Aug 2009

RBC Life Sciences reports on patent-pending, nutritional supplement

RBC Life Sciences, Inc., a provider of proprietary nutritional supplements and wound care/pain management products, announced today the debut of NeuroBright(TM), a patent-pending, nutritional supplement that improved test subjects' learning and memory skills by 50 percent during a recent laboratory trial.

20 Aug 2009

Wraser purchases Trezix oral capsule product from e5 Pharma

WraSer Pharmaceuticals, LLC (WraSer) announced that it has purchased the Trezix® Oral Capsule product from e5 Pharma, LLC. With the purchase, WraSer is granted full rights to market and distribute Trezix® in the United States.

20 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Imagenetix announces retail distribution of InflameAway Celadrin(R) gels for promoting joint health

Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced that InflameAway Celadrin(R) extra strength soft gels for joint health are currently available at the nation's number one drug chain, the number one and number two supermarket stores and the number one club warehouse store. This retail distribution provides a platform for future retail gains as well as additional product launches, including a 100 count value size.

20 Aug 2009

Phrma brushes off Republican leader's attacks

"The prescription drug industry's lobbying arm is defending its deal with President Barack Obama in the wake of criticism from House Minority Leader John Boehner, who charged it with 'appeasing' the Obama administration," The Hill reports.

19 Aug 2009

FDA approves Hiberix Haemophilus influenzae type b vaccine

In response to a U.S. shortage of a vaccine to protect infants from Haemophilus influenzae type b (Hib), GlaxoSmithKline (NYSE: GSK) has received accelerated approval from the FDA (Food and Drug Administration) for Hiberix((R)) [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] as a booster dose in children 15 months through four years of age. Hib is an often severe and potentially deadly bacterial infection that can cause meningitis.

19 Aug 2009

Mylan files lawsuit against Pittsburgh Post-Gazette, Post-Gazette reporters

Mylan Inc. (Nasdaq: MYL) today announced that the company and its subsidiary Mylan Pharmaceuticals Inc. filed a civil lawsuit in the Circuit Court of Monongalia County, W.Va., against the Pittsburgh Post-Gazette, Post-Gazette reporters Len Boselovic and Patricia Sabatini, and others as yet unknown.

19 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

AstraZeneca Canada files a New Drug Submission (NDS) for FluMist in Canada

AstraZeneca Canada Inc. announced today that it has filed a New Drug Submission (NDS) for FluMist(R) (Influenza Vaccine, Live Attenuated Intranasal) with Health Canada.

19 Aug 2009

H1N1 vaccine orders top 1 billion, WHO Says

"Northern hemisphere countries have so far ordered more than one billion doses of swine flu vaccine, the World Health Organisation said Tuesday, sparking warnings over shortages," Agence France-Presse reports. While some countries, including Greece, The Netherlands, Canada and Israel, have ordered enough vaccine to inoculate their citizens, "[o]thers, such as Germany, the United States, Britain and France, have put in orders that would cover between 30 and 78 percent of people," the news service writes.

19 Aug 2009

U.S. FDA approval of miconazole MBT represents a significant milestone for Strativa Pharmaceuticals

Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC).

19 Aug 2009

Omnia Biologics and Aparna Biosciences sign agreement on lentivirus drug development

Biologics contract manufacturer Omnia Biologics, Inc. (Omnia) (Rockville, MD) and drug development company Aparna Biosciences Corp. (AparnaBio) (Rockville, MD) today announced a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical services as well as manufacture of research grade through cGMP grade materials.

19 Aug 2009

CEL-SCI expands work on current H1N1 virus vaccine

CEL-SCI Corporation has announced that it is expanding the scope of its work towards creating a novel treatment and vaccination against the current H1N1 virus, as well as a future mutated form in which the virus has acquired greater morbidity and mortality.

19 Aug 2009

Light-activated delivery system enhances anti-tumour drug potency

The effects of tumour-targeting drugs in mice are significantly enhanced by PCI Biotech's light-activated delivery system, a new study shows. Researchers say this dual therapy approach could be employed to increase the effect and lower the side effects of anti-cancer drugs in humans.

19 Aug 2009

Orient Pharma granted commercialization rights for a drug candidate by DURECT

DURECT Corporation today announced that it has signed a development and license agreement with Orient Pharma Co., Ltd., a diversified multinational pharmaceutical, healthcare and consumer products company with headquarters in Taiwan, under which DURECT has granted to Orient Pharma development and commercialization rights in selected Asian and South Pacific countries to a drug candidate based on DURECT's ORADUR(R) Technology and one specified active pharmaceutical ingredient for the treatment of attention deficit hyperactivity disorder (ADHD).

19 Aug 2009

BioAlliance Pharma's new drug application for oropharyngeal candidiasis treatment accepted by the FDA

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad® (Loramyc®) Mucoadhesive Buccal Tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole Lauriad® delivers the antifungal miconazole via a mucoadhesive buccal tablet that is designed to enable once-daily dosing of the active ingredient at the site of infection.

19 Aug 2009

CSL Biotherapies to supply Afluria influenza vaccines from newly licensed packaging facility

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company’s newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL’s U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

SFDA approves China Pharma Holdings' generic Omeprazole Sodium injection

China Pharma Holdings, Inc., which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that it has received approval from the Chinese State Food and Drug Administration ("SFDA) for the production of generic Omeprazole Sodium injections.

19 Aug 2009